Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.53 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | IDE | P14735 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | SLC6A15 | Q9H2J7 | 1/20 | 0.43 |
| ▸ | OGA | O60502 | 1/20 | 0.43 |
| ▸ | SORD | Q00796 | 1/20 | 0.43 |
| ▸ | SMO | Q99835 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31635767 | 0.82 | TRPV1 (0.51) | TRPV1IDEHRH1SMO | |
| SCHEMBL3530584 | 0.81 | PANK3 (0.59) | KITIDEHRH1SLC6A15SMO | |
| SCHEMBL30796957 | 0.80 | TRPV1 (0.53) | TRPV1 | |
| SCHEMBL12991337 | 0.79 | ALDH1A1 (0.45) | TRPV1HRH1SLC6A15SORDSMO | |
| SCHEMBL1320120 | 0.79 | GPR119 (0.56) | TRPV1 | |
| SCHEMBL3558471 | 0.79 | MAPT (0.51) | KITIDEHRH1SLC6A15SMO | |
| SCHEMBL13037430 | 0.79 | CYP1A2 (0.44) | TRPV1HRH1SLC6A15SMO | |
| SCHEMBL12991440 | 0.79 | ALDH1A1 (0.47) | TRPV1HRH1 | |
| SCHEMBL1877788 | 0.78 | PANK3 (0.58) | TRPV1KIT | |
| SCHEMBL21193615 | 0.78 | TRPV1 (0.62) | TRPV1SORDSMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858786-B2 | Pyrimidines and pyrazines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCOROPATED (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858786-B2 | Pyrimidines and pyrazines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCOROPATED (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858786-B2 | Pyrimidines and pyrazines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCOROPATED (US) | 2010-12-28 | — | — | US | disclosed |
| EP-1877385-A1 | PYRIMIDINES AND PYRAZINES USEFUL AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070093454-A1 | Pyrimidines and pyrazines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-04-26 | — | — | US | disclosed |
| US-20070093454-A1 | Pyrimidines and pyrazines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-04-26 | — | — | US | disclosed |
| US-20070093454-A1 | Pyrimidines and pyrazines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-04-26 | — | — | US | disclosed |
| WO-2006119451-A1 | PYRIMIDINES AND PYRAZINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093454-A1 | Pyrimidines and pyrazines useful as modulators of ion channels | KCNJ1, KCNJ2, KCNJ11 | TRPV1 7/4885KIT 3315/4885IDE 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.